Skip to main content
TempraMed Technologies logo

TempraMed Technologies — Investor Relations & Filings

Ticker · VIVI ISIN · CA88024B1022 LEI · 529900AK4AXUNXYDWH07 CSE Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2025-09-26 M&A Activity
Country CA Canada
Listing CSE VIVI

About TempraMed Technologies

https://tempramed.com

TempraMed Technologies Ltd. develops and markets innovative, temperature-controlled storage solutions for injectable and temperature-sensitive pharmaceuticals, focusing on "last mile" control management for patients and healthcare providers. The company utilizes patented, space-grade insulation technology in its FDA-registered medical devices. Key products include the VIVI Cap, a thermal carrying case for insulin pens and weight loss medications, and the VIVI Epi, a temperature shield for epinephrine auto-injectors (EpiPen). These compact, maintenance-free solutions require no batteries or charging, ensuring medications remain within optimal temperature ranges 24/7/365, thereby safeguarding drug efficacy and minimizing the risk of spoilage due to temperature extremes.

Recent filings

Filing Released Lang Actions
Other material contract(s).pdf
M&A Activity Classification · 1% confidence The document is a legal agreement (Second Amending Agreement) modifying an existing Amended and Restated Share Exchange Agreement under which Greenfield will acquire TempraMed’s securities. This clearly relates to merger/acquisition activity rather than financial reporting, dividends, or governance disclosures. Therefore, it should be classified under M&A Activity (Code: TAR).
2025-09-26 English
Other material contract(s).pdf
M&A Activity Classification · 1% confidence The document is a lock-up agreement restricting sale of shares in connection with an amended and restated share exchange transaction. It is not an earnings release, audit, or dividend notice but a contractual arrangement in support of an M&A/sharing exchange transaction. Therefore it best fits under M&A Activity (TAR).
2025-09-26 English
Other material contract(s).pdf
M&A Activity Classification · 1% confidence The document is a contractual lock‐up agreement entered into in connection with a share exchange transaction between Greenfield and TempraMed Israel, imposing sale restrictions on securityholders as part of the merger/acquisition process. This is not a periodic financial report, a management announcement, nor a regulatory notice but rather part of merger and takeover documentation. Therefore it falls under M&A Activity (Code: TAR).
2025-09-26 English
Other material contract(s).pdf
Share Issue/Capital Change Classification · 1% confidence The document is a contractual “Lock Up Agreement” governing the post‐transaction restrictions on the sale or transfer of shares issued in connection with a share exchange transaction. It is not an earnings, audit, management, or regulatory announcement, but rather part of the capital issuance process tied to the transaction. This falls under “Share Issue/Capital Change” (SHA).
2025-09-26 English
Other material contract(s).pdf
Regulatory Filings Classification · 0% confidence The provided text is a private License Agreement between TempraMed Israel Ltd and an individual licensor. It details patent definitions, grant of license, payments, obligations, confidentiality, and enforcement terms. This is not an annual or interim financial report, earnings release, management discussion, regulatory announcement, board change notice, or any other specified corporate filing type. It is a standalone contractual agreement that does not fit any of the specific categories. Under the classification rules, such miscellaneous agreements fall into the fallback category: Regulatory Filings (RNS).
2025-09-26 English
Other material contract(s).pdf
Regulatory Filings Classification · 0% confidence The document is a bilateral commercial agreement (initial service and loan debenture agreement and subsequent amendment) between TempraMed Israel Ltd and TempraMed Inc. It is not an AGM presentation, financial report (10-K, IR, ER), management or remuneration disclosure, nor any M&A, share issuance, insider trading, dividend notice, or similar corporate filing. It is a private contract rather than a shareholder communication or financial statement. Therefore, it does not match any specific category except the general fallback for miscellaneous filings: Regulatory Filings (RNS).
2025-09-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.